Publications
Publications
-
For an extensive list of Dr. Gelfand's research publications, please refer here.
-
Some of the Gelfand lab’s most important findings in the last decade:
· 2010
First to show severe psoriasis is a risk factor for CV mortality: https://www.ncbi.nlm.nih.gov/pubmed/20037179
· 2011
TNF monotherapy without signal for infection or cancer in meta-analysis of psoriasis RCTs: https://www.ncbi.nlm.nih.gov/pubmed/21315483
First to show psoriasis is associated with increased aortic vascular inflammation, setting up a series of trials: https://www.ncbi.nlm.nih.gov/pubmed/21576552
· 2012
Biologics have lower effectiveness in real world settings: https://www.ncbi.nlm.nih.gov/pubmed/22508874
· 2013
We are the first to show psoriasis is a risk factor for chronic kidney disease: https://www.ncbi.nlm.nih.gov/pubmed/24129480
· 2014
Clear skin is more important than almost clear skin for psoriasis, setting up new performance measures: https://www.ncbi.nlm.nih.gov/pubmed/24928705
· 2015
HTN poorly controlled in patients with psoriasis, as skin severity increases, HTN gets worse: https://www.ncbi.nlm.nih.gov/pubmed/25322196
Risk of MACE similar in psoriasis compared to rheumatoid arthritis: https://www.ncbi.nlm.nih.gov/pubmed/25351522
BSAxPGA correlates well with PASI. This measure is now routinely used in simplified clinical trials: https://www.ncbi.nlm.nih.gov/pubmed/26475541
· 2016
The risk of cancer in psoriasis is small and is driven by NMSC, lymphoma, and lung cancer: https://www.ncbi.nlm.nih.gov/pubmed/26676102
· 2017
We provide a seminal review for clinicians re: comorbidity and psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/28212760
· 2018
The risk of venous thromboembolic disease varies between Pso, PsA, and RA: https://www.ncbi.nlm.nih.gov/pubmed/28444172
Body surface area predicts mortality and diabetes in psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/28843488
https://www.ncbi.nlm.nih.gov/pubmed/29128465
Liver disease is more strongly associated with Pso and PsA than with RA:
https://www.ncbi.nlm.nih.gov/pubmed/29104161
We defined the CV effects of adalimumab and phototherapy vs placebo:
https://www.ncbi.nlm.nih.gov/pubmed/29776990
· 2019:
Stigmatizing views about psoriasis remain widely held in the US: https://www.ncbi.nlm.nih.gov/pubmed/30171876
Phototherapy achieves similar and potentially better patient reported outcomes compared to adalimumab: https://www.ncbi.nlm.nih.gov/pubmed/31163241
We launched the LITE study, a pragmatic trial of home v office phototherapy: